- link Copy Url - [ Share on twitter ](https://twitter.com/intent/tweet?text=Bristol-Myers Squibb and UCLA Enter into a Collaboration Agreement as Part of U.S. Immuno-Oncology Rare Population Malignancy Research Program https://www.3blmedia.com/markdownify/node/65750?absolute=1&via=3blnews "link to 3 B L Media's Twitter") - [ Share on linkedin ](https://www.linkedin.com/shareArticle?mini=true&url=https://www.3blmedia.com/markdownify/node/65750?absolute=1 "link to 3 B L Media's Linkedin") - [ Share on facebook ](https://www.facebook.com/sharer/sharer.php?u=https://www.3blmedia.com/markdownify/node/65750?absolute=1 "link to 3 B L Media's Facebook") - [ email Share via email ](mailto:?subject=Bristol-Myers Squibb and UCLA Enter into a Collaboration Agreement as Part of U.S. Immuno-Oncology Rare Population Malignancy Research Program&body=ESG News from Bristol-Myers Squibb Company https://www.3blmedia.com/markdownify/node/65750?absolute=1 "Share via email") [Responsible Business & Employee Engagement](/CSR-News/responsible-business-employee-engagement) # Bristol-Myers Squibb and UCLA Enter into a Collaboration Agreement as Part of U.S. Immuno-Oncology Rare Population Malignancy Research Program Dec 14, 2015 7:00 AM ET Campaign: [Advancing Science Through Research](/news/campaign/advancing-science-through-research) Monday, December 14, 2015 6:59 am EST, NEW YORK- /3BL Media/ - [Bristol-Myers Squibb Company](http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.bms.com&esheet=51242639&newsitemid=20151214005214&lan=en-US&anchor=Bristol-Myers+Squibb+Company&index=1&md5=60bef099f3fd49ed42c649795814c004)(NYSE:BMY) today announced that they have entered into a collaboration agreement with UCLA as part of Bristol-Myers Squibb’s Immuno-Oncology Rare Population Malignancy (I-O RPM) research program in the U.S. The I-O RPM research program is a multi-institutional initiative with academic-based cancer centers focused on the clinical investigation of immuno-oncology therapeutics as potential treatment options for patients with high risk, poor prognostic cancers, defined as a rare population malignancy. Bristol-Myers Squibb and the David Geffen School of Medicine at UCLA will conduct a range of early phase clinical studies as part of the I-O RPM research program, and Bristol-Myers Squibb will fund positions within UCLA’s fellowship program in the UCLA Division of Hematology/Oncology. “The I-O RPM research program is an important complement to Bristol-Myers Squibb’s broad research and development program for immuno-oncology,” said Laura Bessen, M.D., head of U.S. Medical, Bristol-Myers Squibb. “We look forward to working with UCLA in an effort to continue advancing the science in this innovative field of research and cancer treatment.” About I-O RPM Immuno-oncology is an innovative approach to cancer research and treatment that is designed to harness the body’s own immune system to fight cancer. The I-O RPM research program focuses on significant areas of high unmet need marked by poor outcomes among patients with rare population malignancies. A rare population malignancy is a subpopulation within a higher incident disease population. These patients have aggressive disease with an increased potential for early metastasis to multiple sites and/or are initially refractory or subject to early recurrences with conventional cancer therapies. Existing clinical research provide a strong rationale for further research into the potential of immunotherapies for these cancers. The I-O RPM research program is a multi-institutional initiative with Robert H. Lurie Comprehensive Cancer Center of Northwestern University and the Northwestern Medicine Developmental Therapeutics Institute, Moffitt Cancer Center, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and now UCLA. I-O RPM builds on Bristol-Myers Squibb’s formation in 2012 of the International Immuno-Oncology Network (II-ON), which is a global collaboration between Bristol-Myers Squibb and academia focused on facilitating the translation of scientific research findings into clinical trials and, eventually, clinical practice. About Bristol Myers Squibb Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit [www.bms.com](http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.bms.com&esheet=51242639&newsitemid=20151214005214&lan=en-US&anchor=www.bms.com&index=2&md5=ea89a56506aae7e5874d02db303b705c) or follow us on Twitter at [http://twitter.com/bmsnews](http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Ftwitter.com%2Fbmsnews&esheet=51242639&newsitemid=20151214005214&lan=en-US&anchor=http%3A%2F%2Ftwitter.com%2Fbmsnews&index=3&md5=5787f92baced8688f05de7a26ee40f9d). Bristol-Myers Squibb Forward-Looking Statement This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding the research, development and commercialization of pharmaceutical products. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Among other risks, there can be no guarantee that the immunotherapies discussed in this release will be successfully developed or approved for any of the indications described in this release. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Bristol-Myers Squibb's business, particularly those identified in the cautionary factors discussion in Bristol-Myers Squibb's Annual Report on Form 10-K for the year ended December 31, 2014 in our Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K. Bristol-Myers Squibb undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. ## Contact: Bristol-Myers Squibb Company Media: Sarah Koenig, 609-252-4145, or Investors: Ranya Dajani, 609-252-5330, Bill Szablewski, 609-252-5894, [![Bristol Myers Squibb logo](/sites/default/files/2024-06/bms_logo_300_rgb_2024.png)](/profiles/bristol-myers-squibb-company) ### More from Bristol-Myers Squibb Company ###### [Bristol Myers Squibb Evolves and Expands Standing in the Gaap To Advance More Equitable Care in Multiple Myeloma As Program Marks Ten Years](/news/bristol-myers-squibb-evolves-and-expands-standing-gaap-advance-more-equitable-care-multiple) Apr 1, 2026 6:59 AM ET ###### [A New Era in Schizophrenia Care: National Council for Mental Wellbeing and Bristol Myers Squibb Collaborate to Advance Evidence-Based Care Models](/news/new-era-schizophrenia-care-national-council-mental-wellbeing-and-bristol-myers-squibb) Mar 27, 2026 6:59 AM ET ###### [Early Diagnosis and Local Solutions Are Critical To Combat Lung Cancer](/news/early-diagnosis-and-local-solutions-are-critical-combat-lung-cancer) Mar 23, 2026 8:00 AM ET ###### [Bristol Myers Squibb to be Inaugural Partner for Life Science Cares National Campaign to Advance Health Equity and Fight Food Insecurity](/news/bristol-myers-squibb-be-inaugural-partner-life-science-cares-national-campaign-advance-health) Feb 12, 2026 1:00 PM ET ###### [Robert A. Winn Excellence in Clinical Trials Award Program Announces Third Cohort of Physician-Researchers for the Clinical Investigator Leadership Award](/news/robert-winn-excellence-clinical-trials-award-program-announces-third-cohort-physician) Feb 11, 2026 6:30 AM ET ###### [Bristol Myers Squibb Announces Collaboration with Microsoft to Advance AI-Driven Early Detection of Lung Cancer](/news/bristol-myers-squibb-announces-collaboration-microsoft-advance-ai-driven-early-detection-lung) Jan 22, 2026 6:30 AM ET ###### [Bristol Myers Squibb Foundation Launches National Program to Bolster Mental Health Diversion Initiatives](/news/bristol-myers-squibb-foundation-launches-national-program-bolster-mental-health-diversion) Jan 20, 2026 6:30 AM ET ###### [Building a Healthier Future Together: Strengthening Cancer Care Across Africa Through Partnership](/news/building-healthier-future-together-strengthening-cancer-care-across-africa-through-partnership) Dec 17, 2025 12:15 PM ET